Status | Study |
RECRUITING |
Study Name: PR3-AAV Resilient Remission or PRRR Condition: Granulomatosis With Polyangiitis Date: 2022-05-11 Interventions: 1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15 |
Recruiting |
Study Name: Eosinophilic Granulomatosis With Polyangiitis Cohort Condition: Churg-Strauss Syndrome Date: 2016-09-26 |
Recruiting |
Study Name: Rituximab in Eosinophilic Granulomatosis With Polyangiitis Condition: Eosinophilic Granulomatosis With Polyangiitis (EGPA) Date: 2016-05-20 Interventions: Drug: Rituximab 1 g intravenou |
Recruiting |
Study Name: Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Condition: Granulomatosis With Polyangiitis (Wegener's Granulomatosis) Date: 2015-12-08 Interventions: Drug: Rituximab Standard of ca |
Recruiting |
Study Name: A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis Condition: Wegener's Granulomatosis or Microscopic Polyangiitis Date: 2014-04-14 Interventions: Drug: Methylprednisolone Methy |
Recruiting |
Study Name: Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) Condition: Granulomatosis With Polyangiitis (Wegener's) Date: 2014-03-27 Interventions: Drug: Abatacept Those randomiz |
Recruiting |
Study Name: The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach Condition: Granulomatosis With Polyangiitis Date: 2013-09-06 Interventions: Drug: Prednisone 5 mg/day Subj |
Recruiting |
Study Name: Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) Condition: Granulomatosis With Polyangiitis Date: 2013-01-01 Interventions: Other: Blood samples and clinical data |
Active, not recruiting |
Study Name: A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Condition: Granulomatosis With Polyangiitis Date: 2012-12-13 Interventions: Drug: Rituximab Participants will receive rituximab 375 mg/m^2 IV infusion on Days 1, 8, 15 and 22. Ritu |
Active, not recruiting |
Study Name: An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Condition: Granulomatosis With Polyangiitis Microscopic Polyangiitis Date: 2012-06-04 Interventions: Drug: Rituximab Participants received rituximab at the discretion of their treating physicians. |